Scientific Programme

S 0.1 Late Breaking Clinical Trials
Programme to be announced

S 0.2 ERA-EDTA Registry
1. International comparison of trends in kidney transplantation rates in Europe
Rianne Boenink, Amsterdam, Netherlands
2. Uraemic symptoms and uraemic toxins in the EQUAL study
Ziad Massy, Paris, France
3. Work status and work ability of patients treated with kidney replacement therapy
Rianne de Jong, Amsterdam, Netherlands

S 0.3 ASN Highlights
Programme to be announced

S 0.4 2021 pearls of NDT and CKJ
1. NDT
Kate Stevens, Glasgow, UK
2. CKJ
Pierre Delanaye, Liege, Belgium
Ana Carina Ferreira, Lisbon, Portugal

S 0.5 Avoiding a crash landing of nephrology by creating awareness
1. The burden of kidney disease: the unbearable lightness of neglect
Raymond Vanholder, Ghent, Belgium
2. The burden of COVID-19 on the population with kidney disease
Marlies Noordzij, Groningen, Netherlands
3. US action to create awareness on kidney disease
Murray Sheldon, Washington, DC, USA

S 0.6 Future scenarios for renal disease
1.Climate changes and nephrology
Richard Johnson, Aurora, CO, USA
2. Demographic changes in different part of the world
Hans Groth, St. Gallen, Switzerland
3. Planetary health and burden of life style diseases – what saves the planet saves our health
Peter Stenvinkel, Stockholm, Sweden

S 0.7 Climate change and health: the opinion of the younger generation
1. Global perspective on the climate crisis as a crisis of health
Martin Herrmann, Munich, Germany
2. Repercussions of heatwaves for kidney patients
Christian Witt, Berlin, Germany
3. Perspectives for the coming medical generation regarding the climate crisis
Sylvia Hartmann, Munich, Germany

Nephrology Pearls (closing session)
1. Basic Science and Translational Nephrology
Carsten Wagner, Zurich, Switzerland
2. Epidemiology and Clinical Nephrology
Kate Stevens, Glasgow, UK
3. ESKD and Dialysis
Rukshana Shroff, London, UK
4. Kidney Transplantation
Luuk Hilbrands, Nijmegen, Netherlands

ML 0.1 The analysis of large public databases for study of human disease: the UK Biobank example
Dorothea Nitsch, London, UK

ML 0.2 Achieving Sustainable Development Goals in nephrology care, research and education
Peter J Blankestijn, Utrecht, Netherlands

S 1.1 Acid-base balance in health and kidney disease
1. The renal response to acid(osis)
Francesco Trepiccione, Naples, Italy
2. Acidosis in patients with kidney transplant: origin and impact on outcome
Nilufar Mohebbi, Zurich, Switzerland
3. Alkali treatment and amelioration of kidney disease – uncovering underlying mechanisms
Pedro H Imenez Silva, Zurich, Switzerland

S 1.2 A new look at tubular functions
1. Paracellular transport via claudins is essential for normal kidney function
Markus Bleich, Kiel, Germany
2. Inherited defects of the proximal tubule reveal important pathways
Richard Warth, Regensburg, Germany
3. How to build a tubular epithelium?
Kai Schmidt-Ott, Berlin, Germany

S 1.3 Phosphate and other minerals
1. Phosphate and vascular calcification: new avenues for treatment
Jakob Voelkl, Linz, Austria
2. Klotho: effects in kidney, heart and brain
Orson Moe, Dallas, TX, USA
3. Inhibition of intestinal and renal phosphate transport as new strategy to treat hyperphosphatemia in CKD
Carsten Wagner, Zurich, Switzerland

S 1.4 Electrolytes: renal transport and endocrine control
1. Gender effects on tubular (salt) handling
Alicia McDonough, Los Angeles, CA, USA
2. Renal potassium sensing and control of blood pressure
Johannes Loffing, Zurich, Switzerland
3. Glucocorticoids and hypertension revisited
Matthew A Bailey, Edinburgh, UK

ML 1.1 The renal lymphatic system
Dontscho Kerjaschki, Vienna, Austria

ML 1.2 Sodium: from gut microbiome to inflammation and hypertension
Nicola Wilck, Berlin, Germany

S 2.1 Diagnosis and treatment of rare disease in children and adult CKD
1. Treatment of patients with X-linked hypophosphatemia with borusumab: advances and limitations
Farzana Perwad, San Francisco, CA, USA
2. Is ADPKD a paediatric disease?
Francesco Emma, Rome, Italy
3. Mendelian randomization reveals causative factors for kidney function impairment
Sehoon Park, Seoul, South Korea

S 2.2 Extracellular vesicles and kidney diseases: from bio-markers to therapeutic bio-products
1. Extracellular vesicles from urine and beyond
Alicia Llorente, Olso, Norway
2. EVs as markers/mediators of vascular ageing
Vincenzo Cantaluppi, Novara, Italy
3. Exosomes and microvesicles as biomarkers in renal physiology and diseases
Diana Karpman, Lund, Sweden

S 2.3 Preeclampsia and kidney in 2021
1. Endothelial dysfunction and activation in preeclampsia
Speaker assigned (to be confirmed soon)
2. Senescence and preeclampsia
Vesna Garovic, Rochester, MN, USA
3. Preeclampsia and future renal disease
Giorgina Piccoli, Le Mans, France

S 2.4 Networks and registries in rare kidney diseases
1. ERKNet and its future perspectives
Franz Schaefer, Heidelberg, Germany
2. Registries in paediatric nephrology
Maria Gema Ariceta Iraola, Barcelona, Spain
3. PKD registries
Albert Ong, Sheffield, UK

S 2.5 Updates on ADPKD
1. Metabolic reprogramming in ADPKD
Alessandra Boletta, Milan, Italy
2. The role of chloride secretion in ADPKD
Bjorn Buchholz, Erlangen, Germany
3. Imaging and genotyping to predict the outcome of ADPKD
Vicente Torres, Rochester, MN, USA

S 2.6 An integrated view of ADTKD, an emerging clinical and genetic entity
1. Clinical and genetic spectra of ADTKD
Eric Olinger, Zurich, Switzerland
2. Cellular mechanisms, genotype to phenotype
Luca Rampoldi, Milan, Italy
3. ADTKD-MUC1 – from diagnostics to mechanisms
Stanislav Kmoch, Prague, Czech Republic

ML 2.1 Diagnosis and management of nephrotic syndrome in children: clinical practice guidelines from IPNA, ESPN and ERKNet
Dieter Haffner, Hannover, Germany

S 3.1 COVID-19 pandemic
1. COVID-19 and history – a perspective from the great influenza pandemic of 1918
Robert Unwin, London, UK
2. COVID-19 in Europe – clinical experience and learnings
Ron Gansevoort, Groningen, Netherlands
3. COVID-19 trials and vaccines – the future?
Martin Landray, Oxford, UK

S 3.2 News in glomerulonephritis treatment
1. IgA nephropathy: is immunosuppression needed?
Jürgen Floege, Aachen, Germany
2. Vasculitis and complement inhibition
Vladimir Tesar, Prague, Czeck Republic
3. GWAS in glomerular diseases
Adam Levine, London, UK

S 3.3 Membranous nephropathy: insights from recent clinical trials
1. The role of anti-PLA2R monitoring
Pierre Ronco, Paris, France
2. Rituximab as first line therapy
Giuseppe Remuzzi, Bergamo, Italy
3. Back to basics. Cyclophosphamide/steroids
Manuel Praga, Madrid, Spain

S 3.4 Onconephrology
1. High cut-off filters and multiple myeloma
Paul Cockwell, Birmingham, UK
2. Cancer immunotherapies (checkpoint inhibitors, CAR-T cells, IL-2) and the kidney
Laura Cosmai, Milan, Italy
3. Haemathological disorders in transplant recipients
Jolanta Malyszko, Warsaw, Poland

S 3.5 Complicated Lupus Nephritis
1. Management of refractory lupus nephritis
Hans-Joachim Anders, Munich, Germany
2. Urinary exosomal miRNA expression profile in lupus nephritis
Benedetta Bussolati, Turin, Italy
3. Improved clarity of definitions and classification of glomerular lesions in lupus nephritis
Agnes Fogo, Nashville, TN, USA

S 3.6 ANCA vasculitis prognostic and treatment
1. ANCA vasculitis and treatment. Where are we now?
David Jayne, Cambridge, UK
2. Urinary CD163 in antineutrophil cytoplasm antibody-associated glomerulonephritis
Gema Fernandez-Juarez, Madrid, Spain
3. Renal risk score for ANCA vasculitis
Juan Manuel Mejia Vilet, Mexico City, Mexico

S 3.7 Kidney stones
1. From crystals to CKD
Felix Knauf, Berlin, Germany
2. Urate transporters, gout and urate nephropathy
Olivier Bonny, Lausanne, Switzerland
3. ABC of Randall’s plaques and stones: from rare diseases to calcium nephrolithiasis
Emmanuel Letavernier, Paris, France

S 3.8 Up-to-Date on Alport Syndrome
1. Different genes for different basement defects: genotype/phenotype correlations
Rachel Lennon, Manchester, UK
2. Ongoing clinical trials
Michelle Rheault, Minneapolis, MN, USA
3. New pathogenetic mechanisms and therapeutic implications
Alessia Fornoni, Miami, FL, USA

S 3.9 The nephrotoxicity of commonly used medications: what is the evidence and what are the alternatives
1. Proton pump inhibitors
Laurie A Tomlinson, London, UK
2. Oral anticoagulants
Sergey Brodsky, Columbus, OH, USA
3. Paracetamol
Vanessa Perez-Gomez, Madrid, Spain

ML 3.1 Kidney transplant suitability for patients with prior cancers: what the nephrologist should know?
Alicja Dębska-Ślizień, Gdańsk, Poland

ML 3.2 C3 glomerulonephritis and membranoproliferative glomerulonephritis: different diseases, same treatment?
Marina Noris, Bergamo, Italy

ML 3.3 Kidney allograft fibrosis: what we have learned from latest translational research studies
Daniel Seron, Barcelona, Spain

ML 3.4 Update on diagnosis and therapy for non-AL amyloidosis
Tamer Rezk, London, UK

ML 3.5 Bardet-Biedle Syndrome: from clinic to omics
Miriam Zacchia, Naples, Italy

ML 3.6 Pathogenesis and management of nephrotic syndrome
Speaker assigned (to be confirmed soon)

ML 3.7 Leveraging animal models for onconephrology research
Anna Capasso, Austin, TX, USA

ML 3.8 Papal renal stone disease: from Saint Peter to St. John Paul II (34-2005)
Natale Gaspare De Santo, Naples, Italy

S 4.1 New treatment targets to halt CKD progression
1. SGLT2-inhibition – the new standard?
Maria Jose Soler, Barcelona, Spain
2. Non-steroidal MRA – an emerging option?
Christian Rump,  Düsseldorf, Germany
3. Targeting inflammation pathways – the future?
Timo Speer, Homburg/Saar, Germany

S 4.2 Microbiome in CKD
1. Personalized targeting of the microbiome
Speaker assigned (to be confirmed soon)
2. Microbiota in CKD: how promising are gut-targeted approaches?
Carmela Cosola, Bari, Italy
3. Effects of established drugs on microbiome composition
Speaker assigned (to be confirmed soon)

S 4.3 Uraemic toxicities
1. Uraemic toxins and endothelium
Andréa Emilia Marques Stinghen, Curitiba, Brazil
2. Uraemic toxins and macrophages
Lucie Henaut, Amiens, France
3. Uric acid and allopurinol in CKD: a paradigm change
Björn Meijers, Leuven, Belgium

S 4.4 CKD and metabolic disorders: the common cognitive outcome
1. Cognitive impairment in CKD
Davide Viggiano, Naples, Italy
2. Cognitive impairment in diabetes and metabolic syndrome
Speaker assigned (to be confirmed soon)
3. Cognitive impairment and albuminuria/hypertension
Pilar Delgado Martinez, Barcelona, Spain

S 4.5 Preventing kidney ageing
1. The potential influence of the genetic background
Speaker assigned (to be confirmed soon)
2. Non-genetic factors driving kidney ageing
Anette Melk, Hannover, Germany
3. Preserving Klotho expression
Maria Dolores Sanchez-Niño, Madrid, Spain

S 4.6 New nutritional targets in CKD
1. Are low or very low protein diets still useful and attractive treatment in CKD?
Denis Fouque, Lyon, France
2. Ketogenic diet: a new tool to improve renal cyst growth in ADPKD
Thomas Weimbs, Santa Barbara, CA, USA
3. Role of kidney proximal tubules to balance nutrient and uremic toxins levels
Rosalinde Masereeuw, Utrecht, Netherlands

S 4.7 SGLT2-inhibitors in CKD without diabetes
1. How do SGLT2 inhibitors work?
Volker Vallon, San Diego, CA, USA
2. What does imaging tell us?
Roland Schmieder, Erlangen, Germany
3. Non-diabetic heart failure and CKD
Faiez Zannad, Nancy, France

S 4.8 Randomized trials – Slowing the progression of CKD
DAPA-CKD
1. The DAPA-CKD trial. Primary results and insights from a kidney perspective, including:
• Outcomes by CKD aetiology including IgA nephropathy and FSGS
• Outcomes in Stage 4 CKD
• In-depth data on mortality
Hiddo Lambers Heerspink, Groningen, Netherlands
2. DAPA-CKD – thinking beyond kidney disease. Glycaemic and cardiovascular outcomes, including:
• Outcomes by diabetes status
• Outcomes by baseline cardiovascular disease
Peter Rossing, Gentofte, Denmark
3. Clinical insight – How should we use SGLT2 inhibitors in nephrology?
David Wheeler, London, UK
2. FIDELIO-DKD
Speakers to be confirmed
3. The Big Three: how RASi, SGLT2i & MRA will change the treatment landscape for kidney patients
George Bakris, Chicago, IL, USA

ML 4.1 Epigenetic DNA and histone modifications for CKD treatment
Alberto Ortiz, Madrid, Spain

ML 4.2 MicroRNA and kidney pathophysiology
Laurent Metzinger, Amiens, France

ML 4.3 Regulation of extracellular volume in the brain: Glymphatics
Speaker assigned (to be confirmed soon)

ML 4.4 Potassium and mortality
Ewout J. Hoorn, Rotterdam, Netherlands

ML 4.5 CKD and prognosis, mortality, hospitalization
Marcello Tonelli, Calgary, Canada

ML 4.6 Coffee and mortality in CKD
Miguel Bigotte Vieira, Lisbon, Portugal

ML 4.7 Plant based diets in CKD: benefits and risks
Juan Jesus Carrero, Stockholm, Sweden

ML 4.8 Hydration and CKD: Neither too much nor too little?
Sandra Wagner, Paris, France

S 5.1 Non-dialysing in the XXI Century
1. Non-dialysis in ESRD: how to offer conservative care
Speaker assigned (to be confirmed soon)
2. Dialysis withdrawal: time and communication
Patrick Finne, Helsinki, Finland
3. Survival outcomes in elderly frail patients
Vanita Jassal, Toronto, Canada

S 5.2 COVID-19 in haemodialysis patients
1. Prevention strategies for minimizing SARS-CoV-2 infection in dialysis facilities
Mario Cozzolino, Milan, Italy
2. Infection control in dialysis units
Patricia De Sequera Ortiz, Madrid, Spain
3. Outcomes in dialysis patients infected with SARS-CoV-2
Marian Goicoechea, Madrid, Spain

S 5.3 Innovations in haemodialysis
1. The long journey towards a portable/wearable dialysis. What can we expect in the future?
Karin Gerritsen, Utrecht, Netherlands
2. New haemodialysis therapies: HDx therapy – new membranes and others. Do they mean any real improvement?
Marie Evans, Stockholm, Sweden
3. How to reduce organ ischemia during haemodialysis: can modern technologies help us?
Chris McIntyre, Toronto, Canada

S 5.4 Volume and blood pressure control in dialysis
1. The dialysis prescription for optimal volume control: a KDIGO report
Jennifer Flythe, Chapel Hill, NC, USA
2. Timing of antihypertensive medications in dialysis: effects of BP control and intradialytic hypotension
Speaker assigned (to be confirmed soon)
3. Intradialytic hypertension: an ignored killer?
Pantelis Sarafidis, Thessaloniki, Greece

S 5.5 Everyday issues in dialysis
1. How to dose haemodialysis: KtV, signs/symptoms, blood pressure, convection volume, something else?
Andrew Davenport, London, UK
2. How to choose the best sodium, potassium and bicarbonate level for an individual patient?
Christian Combe, Bordeaux, France
3. How to incorporate patient related outcome measures in to everyday dialysis care?
Alferso Abrahams, Utrecht, Netherlands

ML 5.1 Comprehensive Conservative Care: what doctors say, what patients hear
Luc Frimat, Nancy, France

ML 5.2 Nutritional impact of HDF, a randomized trial
Pablo Molina, Valencia, Spain

S 6.1 News in peritoneal dialysis
1. Growth of peritoneal dialysis post-COVID-19
Edwina A Brown, London, UK
2. Biocompatible solutions and new osmotic agents
Claus Peter Schmitt, Heidelberg, Germany
3. Incremental peritoneal dialysis prescription
Simon Davies, Stoke-on-Trent, UK

S 6.2 Volume control in peritoneal dialysis
1. Which biomarkers should we use?
Anabela Rodrigues, Porto, Portugal
2. Does bioimpedance have a role in volume control?
Wim Van Biesen, Ghent, Belgium
3. The anuric patient – is there a space for weekly hypertonic solutions?
Speaker assigned (to be confirmed soon)

S 6.3 PD vs HD: similarities and differences, an endless debate
1. Sleep apnea and sleep quality in dialysis patients; an emerging cardiovascular risk factor?
Francesca Mallamaci, Reggio Calabria, Italy
2. Technical methods for volume evaluation in ESKD; are there differences between haemodialysis and peritoneal dialysis?
Robert Ekart, Maribor, Slovenia
3. Regulation of central haemodynamics and blood pressure in haemodialysis and peritoneal dialysis; is “more stable” also better?
Olga Balafa, Ioannina, Greece

ML 6.1 Assisted PD: strategies and outcomes
Anna Giuliani, Vicenza, Italy

ML 6.2 Mistakes we make in treating peritonitis
Mark Lambie, Stoke-On-Trent, UK

S 7.1 Translational research in kidney transplant: From bench to bedside
1. Genetic diagnostic biomarkers and new predictors of outcomes in kidney transplantation
Maarten Naesens, Leuven, Belgium
2. T-cell exhaustion in kidney transplant recipients
Paolo Cravedi, New York, NY, USA
3. Cell-free DNA a valuable tool to monitor acute rejection after kidney transplantation
Daniel Abramowicz, Antwerp, Belgium

S 7.2 Recent advances in kidney transplantation: focus on immunity
1. NON-HLA Incompatibilities: what’s new
Rainer Oberbauer, Vienna, Austria
2. Targeting immuno-inflammation in kidney transplantation: a new weapon against organ fibrosis
Gianluigi Zaza, Verona, Italy
3. Immunologic monitoring and biomarkers in kidney transplant recipients
Chan-Duck Kim, Daegu, South Korea

S 7.3 Transplant clinical medicine
1. Deceased Donor-initiated Chains: a way to avoid long waiting list
Lucrezia Furian, Padua, Italy
2. Organ preservation and reconditioning: the dream comes true
Henri Leuvenink, Groningen, Netherlands
3. Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?
Jadranka Buturovic, Ljubljana, Slovenia

S 7.4 New mechanisms of graft damage in kidney transplantation
1. Preserving the donor: new therapeutic approaches
Cees van Kooten, Leiden, Netherlands
2. Machine perfusion: optimizing the protocol for better preservation
Rutger J. Ploeg, Oxford, UK
3. Inflammaging and complement system: from acute kidney injury to chronic graft damage
Giuseppe Castellano, Foggia, Italy

ML 7.1 Recurrent glomerulonephritis after kidney transplantation: an update
Piergiorgio Messa, Milan, Italy

ML 7.2 Oxygenation of the transplanted kidney
Kai-Uwe Eckardt, Berlin, Germany

S 8.1 New concepts in cardiovascular disease in CKD patients
1. Treatment of atrial fibrillation in patients with CKD: a way between Scylla and Charybdis?
Charles Ferro, Birmingham, UK
2. Blood-pressure insensitive arterial stiffness: the major cardiovascular risk factor in ESRD?
Gerard London, Paris, France
3. The role of endothelial glycocalyx in health and disease
Mehmet Kanbay, Istanbul, Turkey

S 8.2 Diabetic nephropathy 2021
1. Nephroprotective antidiabetic drugs: a prescription algorithm
Clara Garcia Carro, Barcelona, Spain
2. Beyond antidiabetic drugs for DKD: what is new and upcoming
Beatriz Fernandez Fernandez, Madrid, Spain
3. How should future trials for DKD look like
Christoph Wanner, Würzburg, Germany

S 8.3 Hypertension treatment in special renal populations
1. Hypertension management in transition from CKD to ESRD
Aldo Peixoto, New Haven, CT, USA
2. Hypertension in patients with renal transplantation: current concepts and future directions
Jean-Michel Halimi, Tours, France
3. Hypertension in children and adolescents in CKD
Stella Stabouli, Thessaloniki, Greece

S 8.4 KDIGO clinical practice guideline on diabetes management in CKD
1. HbA1c and beyond
Peter Rossing, Gentofte, Denmark
2. Standard-of-care and self-management
Speaker assigned (to be confirmed soon)
3. Organ protection: the new concept
Speaker assigned (to be confirmed soon)

S 8.5 KDIGO BP in CKD controversial guideline 2021
1. Lowering systolic BP in CKD to <120 mm Hg is reasonable - Con Indranil Dasgupta, Birmingham UK
– Pro
Alfred C Cheung, Salt Lake City, UT, USA
2. BP measurement in the office: Standardized measurement is vital and feasible
– Con
Speaker assigned (to be confirmed soon)
– Pro
Rajiv Agarwal, Indianapolis, IN, USA

ML 8.1 Fibromuscular dysplasia: much more than a rare disease
Alexandre Persu, Brussels, Belgium

ML 8.2 Renal histology in patients with type 2 diabetes: the hidden role of vascular damage
Esteban Porrini, La Laguna, Tenerife, Spain

ML 8.3 Salt and immunity
Bernardo Rodriguez Iturbe, Maracaibo, Venezuela

S 9.1 AKI in special situations
1. AKI in oncology patients
Andrzej Wiecek, Katowice, Poland
2. COVID-19 and AKI
Fabio Malberti, Cremona, Italy
3. AKI: a true risk or predictor of CKD?
Claudio Ronco, Vicenza, Italy

S 9.2 What progress in AKI?
1. AKI alerting systems, AI, biomarkers and imaging
Nick Selby, Nottingham, UK
2. AKI repair or regeneration: what to target, when and how?
Paola Romagnani, Florence, Italy
3. AKI long-term consequences
Carmine Zoccali, Reggio Calabria, Italy

S 9.3 Endocannabinoids and kidney
1. Cannabinoid receptor and hepatorenal syndrome
Pal Pacher, Rockville, MD, USA
2. The role of cannabinoid signalling in chronic kidney diseases
Gabriella Gruden, Turin, Italy
3. Cannabinoid and diabetic nephropathy
Ariela Benigni, Bergamo, Italy

S 9.4 New aspects in AKI prevention and treatment
1. Cost-effective prevention strategies for AKI
Melanie Meersch, Münster, Germany
2. “Subclinical” AKI – does it matter?
Jill Vanmassenhove, Ghent, Belgium
3. New treatment options for AKI – does anything work?
John A. Kellum, Pittsburgh, PA, USA

ML 9.1 AKI biomarkers as prognostic marker for development of CKD
Danilo Fliser, Homburg/Saar, Germany

ML 9.2 AKI and cancer
Ben Sprangers,  Leuven, Belgium

ML 9.3 Inflammatory cascade in acute kidney injury
Speaker assigned (to be confirmed soon)

ML 9.4 New data on transcriptomics and proteomics of COVID 19 in the kidney
Tobias Huber, Hamburg, Germany